- BioNTech (BNTX, Financial) showcases its oncology pipeline including mRNA therapies at the AACR Annual Meeting 2025 in Chicago.
- BNT327 and BNT116 demonstrate significant anti-tumor activity in preclinical and early clinical trials, respectively.
- Over 20 active Phase 2 and 3 clinical trials are ongoing with multiple data readouts expected in 2025 and 2026.
BioNTech SE (NASDAQ: BNTX) is set to unveil pivotal research findings from its diverse oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago from April 25 to April 30, 2025. The company will highlight advances across its mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies.
Among the key developments, BioNTech will present data on BNT327, an innovative PD-L1xVEGF-A bispecific antibody. Preclinical studies of BNT327 have demonstrated its dual capability to inhibit both PD-1/PD-L1 and VEGF-A/VEGFR2 signaling, resulting in superior anti-tumor activity compared to monotherapy approaches.
The event will also feature early clinical results from the Phase 1 LuCa-MERIT-1 trial involving BNT116, an mRNA cancer immunotherapy, in combination with cemiplimab for treating frail patients with advanced non-small cell lung cancer (NSCLC). Preliminary data indicates promising anti-tumor responses and a manageable safety profile.
Additionally, BioNTech will present collaborative work on BNT314/GEN1059 in partnership with Genmab. This EpCAMx4-1BB bispecific antibody, when combined with PD-1 blockade, showed enhanced anti-tumor activity and delayed tumor progression in models unresponsive to single-agent treatments.
BioNTech is actively conducting more than 20 Phase 2 and 3 trials across multiple solid tumor indications. The company is strategically advancing its aim to become a multi-product oncology entity with a wide-scale pipeline poised for significant data readouts in 2025 and 2026.
